Secondary progressive: This is often after a few years of relapsing-remitting MS. The pattern changes from a relapsing pattern to progressive in between attacks, usually with fewer attacks
Sensory symptoms
Motor symptoms Other symptoms (changes in sensation) (changes in motor function) numbness weakness heat sensitivity tingling difficulty walking fatigue other abnormal tremor emotional changes sensations ("pins bowel/bladder problems cognitive changes and needles," pain) poor coordination visual disturbances stiffness dizziness Primary progressive: Gradual onset from the beginning, no attacks. This seems to occur in the older adult age group.
Progressive relapsing: This is a rare form, and begins with a progressive course, while later developing attacks.
Fulminant: Very severe, rapidly progressive MS. This is a rare form of MS.
Most pediatric cases of multiple sclerosis are of the relapsing-remitting variety. Some children do well, with long periods of time between relapses. Some seem to have a more rapidly progressive course.
What causes or risk factors are associated with multiple sclerosis?
There has been extensive research on MS over the past 50 years. While we still do not know the cause of MS, we do know that it is an inflammatory disorder of the central nervous system that occurs in people with a tendency to such a problem. We know that about 350,000 people in the United States have MS, about one in a thousand people. We know that it is more common further north and south of the equator, though we are still unsure why this is.
Females tend to get MS about 3 times as often as males, a rate which is similar to other immune diseases. In children, this ratio may be even higher, with most of the patients being female. Girls with MS are more likely to have initially sensory symptoms (e.g., numbness and tingling) than boys. In addition, girls tend to recover more from their initial episode of MS than boys do.
MS is more common in Caucasians, but can occur in other populations. It is not contagious nor is it infectious. There may be a link with reduced vitamin D levels and perhaps with decreased sun exposure. In children with MS, there may be an increased link with exposure to Epstein-Barr virus. Most people with MS are diagnosed after the age of 18. Only about 3% to 5% of all MS patients have symptoms beginning in childhood.
We know that there is a genetic component to MS. Having a mother or father with MS increases the risk of having MS to about 3% to 5% lifetime, and having an identical twin with MS increases the risk to about 30%. However, many people with MS have no close family members with the disease.
There is nothing that an individual with MS either did to cause the disease to happen or can do to stop the disease from following its natural course. We know that emotional stress may increase the symptoms of MS. We also know that attacks of MS are more likely after infections. There does not seem to be any association with physical trauma or surgical procedures and MS, nor do these seem to make MS worse.
H Ho ow w i is s M MS S d di ia ag gn no os se ed d? ? W Wh ha at t t te es st ts s a ar re e u us se ed d? ? Multiple sclerosis is often difficult to diagnose. This is because there is no single test or finding on the examination that makes the diagnosis and because the disorder varies from person to person. In most cases there is a history of neurological symptoms that come and go over years. The neurological examination may show changes that suggest problems with the spinal cord or brain. The MRI may show areas of abnormality that suggest MS, though the MRI in itself does not 'make the diagnosis.' Spinal fluid testing may show that the immune system is active in and around the brain and spinal cord, supporting the diagnosis. Evoked potentials may assist in diagnosis. All of these need to be put together by the physician to determine if MS is the actual diagnosis.
Even when all the tests are done, some people cannot be diagnosed for years after the beginning of symptoms. An international panel of MS experts recently revised the ways that MS is diagnosed, providing a framework for clinicians to use in making the diagnosis. These new diagnostic criteria (The McDonald criteria) allow the diagnosis of MS if MRI scanning shows new lesions forming over time, making even earlier diagnosis possible. Even with these advances, there are some people where the diagnosis may be uncertain for years, due to the complexity and variation of MS.
In the pediatric age group, diagnosis is even more complex than for adults. This is because there are a large number of disorders that occur in childhood that may mimic MS. For example, acute disseminated encephalomyelitis (ADEM) is more common in childhood and may be confused with MS. Treatment for this disorder is different from MS in that ADEM is usually a one-time illness, and does not require treatment after the initial acute episode.
There are a variety of rare diseases, some genetic, some infectious, some due to other illnesses, that need to be distinguished from MS. Expert evaluation of the clinical history and physician examination, MRI appearance, cerebrospinal fluid, and other diagnostic testing is key to differentiating these other disorders from MS.
Factors which seem to predict a second attack of MS in children include optic neuritis, age greater than 10 years, or an MRI suggestive of MS with multiple well-defined periventricular or subcortical lesions. W Wh ha at t i is s t th he e M Me el ll le en n C Ce en nt te er r a ap pp pr ro oa ac ch h t to o t tr re ea at tm me en nt t? ? At the Mellen Center, patients may meet with one or more members of the care team, depending on individual needs. On the first visit, patients typically meet with a neurologist, who is primarily responsible for managing the patient's medical care. At future visits, patients will also meet with a clinical nurse specialist or a physician assistant who will discuss any concerns about MS and offer suggestions for special problems related to the disease, including spasticity, pain, bowel, bladder or skin problems. The clinical nurse specialist or physician assistant works closely with the neurologist to carry out the individual's care plan.
After a thorough medical history and complete physical evaluation, the Mellen Center team develops an individualized care plan to meet the patient's specific needs. In addition to elements recommended by each member of the Mellen Center team, a care plan also may include specific components requested by the patient, family members or a family doctor.
Follow-up visits are scheduled with one of the clinical nurse specialists or physician assistants who will evaluate the current medical status and discuss treatment plans and options with the patietn and one of the Mellen Center physicians. Additional appointments may be scheduled with a physical or occupational therapist, a psychologist, or a social worker, if necessary.
Team members meet regularly to discuss the individual's progress and fine-tune care plans as needed. Team meetings are an effective means to monitor the flare-ups and remissions that are characteristic of MS. Team members help patients and their families prepare for these changes.
How is multiple sclerosis treated?
D Di is se ea as se e m mo od di if fy yi in ng g a ag ge en nt ts s Since the first FDA-approved medication became available in 1993, a total of six medications have been FDA approved for use in multiple sclerosis. Each of these medications in some way alters the course of MS. Each medication is available in injection form only.
In general, the medications reduce the frequency of exacerbations of MS, reduce the amount of activity seen on MRI scanning, and may slow progression of MS. Each medication has its own side effects and risks. All of the approved medications have information materials to guide patient education provided by the manufacturer. In addition, the National Multiple Sclerosis society provides information on all of these medications at the following website: In general, one of four treatments is used as a first-choice medication for MS: interferonbeta-1a (either in an intramuscular once a week dosing or in a subcutaneous three times a week dosing); interferon-beta-1b (every other day subcutaneous dosing); and copolymer (daily subcutaneous dosing). In large research trials in patients with relapsing MS, each of these medications showed a similar reduction of attack frequency which was the primary measure of effect in these trials.
Each differs in the frequency and route of administration, as well as in the side effect profile. For example, the interferons in general may cause flu-like symptoms (fever, chills, muscle aches, fatigue) after each injection. This side effect may be treated with medications such as acetaminophen or ibuprofen, and in general tends to lessen over time. Copolymer tends to give injection site reactions such as swelling, redness, itching, and occasionally an atrophy of the tissues under the skin at the injection site causing indentation of the skin.
The interferon medications require monitoring of blood work every three to six months to ensure that liver function and blood counts do not change significantly. Interferon-beta-1b may rarely cause a breakdown of the skin at the injection site which requires the medication to be stopped. All of these medications have been used in thousands of patients over years and have a good safety record.
Rare side effects of the interferons include immune inflammation of the liver, altered kidney function, and occasionally an increase in symptoms of depression. In general, copolymer does not have major risks other than skin reactions.
None of the currently available medications for MS have been tested in large studies in the pediatric age group. However, the standard agents listed above have been used in pediatric patients with similar side effects to adult patients and apparently with benefit. Small case series of each treatment have been published. While these cannot definitely document a clinical effect of the medications, they do seem to mirror the adult response to these medications in terms of side effects and reduction in relapse rate. Dosing schedules vary and the specific dose of each medication at different times in childhood is unclear.
Mitoxantrone and natalizumab are powerful medications which are usually reserved for patients with more severe MS or MS that does not respond to standard front line agents. Both have significant side effect profiles. Neither has been extensively tested in the pediatric population to date.
Other medications have been used in MS that are not FDA-approved at this time. For example, sometimes medications that alter the immune system are added to one of the standard agents. Azathioprine, methotrexate, mycophenolate mofetil, and other agents have all been used either alone or in combination with standard injectable agents. These are usually used when the injectable agent alone does not seem to be effective. Again, there are limited case reports of use of such agents in childhood. Choosing to do this is complex and should be done by a physician experienced in treating MS.
There are other medications which have been used from time to time in MS, usually after other standard agents have failed. IVIG is a blood product that in some studies was shown to be helpful in relapsing MS. Cyclophosphamide is a chemotherapy which has been used on and off in MS for many years and which may be used in difficult-to-treat MS. Rituximab is an antibody treatment that recently has been shown to have a powerful effect in multiple sclerosis, but with a risk of causing infections due to suppression of the immune system. All three of these medications are used under the guidance of a physician experienced in the care of patients with multiple sclerosis.
Plasmapheresis is a technique for cleaning antibodies out of the blood stream. It has been used in a number of neurological and immunological diseases. A recent study showed that plasmapheresis is helpful for patients with a severe attack of MS not responding to standard steroid therapy. It requires specialized equipment and is not generally used as a long term treatment. 
